Noveris Health Sciences Inc (MYCOF)
Noveris Health Sciences Inc. is a healthcare company listed on OTC Markets as common stock. The Vancouver-based biotechnology firm focuses on research, development, and commercialization of psilocybin-based products aimed at mental health conditions, with an emphasis on nicotine addiction and post-traumatic stress disorder. Its development pipeline includes MYCO-005, MYCO-006, and MYCO-007, which are associated with MDMA and psilocybin analogs. The company also works with Applied Pharmaceutical Innovation on drug discovery and development programs involving empathogenic and entactogenic compounds. Founded in 2013, the company changed its name from Mydecine Innovations Group Inc. to Noveris Health Sciences Inc. in February 2026.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-MYCO.F
|
—
|
—
|
—
|
—
|
—
|
—
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 28, 2026
|
43.4x
|
-30.9x
|
—
|
41.64 M
|
48.918 M
|
0.7%
|
99.9%
|
-254.5
|
—
|
-17.7%
|
